All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Is CAR T-cell therapy advanced enough to be used for the treatment of AML?
Bookmark this article
During the 2nd European CAR T Cell Meeting in Sitges, ES, the AML Global Portal was delighted to speak to Arnon Nagler, Chaim Sheba Medical Center, Tel Hashomer, IL. We asked: Is CAR T-cell therapy advanced enough to be used for the treatment of AML?
Arnon Nagler explains CAR T-cell therapy for the treatment of AML is complicated but it is progressing, he discusses the challenges such as off-target effects because there is no recognized optimal target antigen in AML. He also talks about patient outcomes in studies that infused patients that have AML with CAR T.
Is CAR T-cell therapy advanced enough to be used for the treatment of AML?
More about...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox